Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progression

By sjmartinez • February 17, 2023

Khanna D, Maher TM, Volkmann ER, Allanore Y, Smith V, Assassi S, Kreuter M, Hoffmann-Vold AM, Kuwana M, Stock C, Alves M, Sambevski S, Denton CP. Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progression. RMD Open. 2023 Feb;9(1):e002859. doi: 10.1136/rmdopen-2022-002859. PMID: 36796874; PMCID: PMC9936273.

Tags: Autoimmune Diseases, Publications, Pulmonary fibrosis, Rheumatology, Scleroderma, Systemic, Therapeutics

Stress Trajectory and Hypertension 2 to 7 Years After Delivery: A nuMoM2b-HHS Study

Nuckols VR, Barone Gibbs B, Brewer BC, Gaffey AE, Greaney JL, Patterson F, Greenland P, Saade GR, Grobman WA, Yee LM, Bairey Merz CN, Chung[...]

Incidence and predictors of postoperative recall of propofol injection pain: a prospective observational cohort pilot study

Bellouni G, Clanet M, Touihri K, Delaporte A, Boulos NM, Kim K, Grogan T, Alexander B, Coeckelenbergh S, Joosten A. Incidence and predictors of postoperative[...]

From Insight to Impact: Advancing Learning Health System Capability Through a System-Wide Quality Improvement Symposium

Dermenchyan A, Seiden DS, Bhayani M, Song A, Venkatesan N, Sharma K, Pandrangi K, Han MA. From Insight to Impact: Advancing Learning Health System Capability[...]